Professional
Added to YB: 2025-12-05
Pitch date: 2025-12-03
NAGE [neutral]
Niagen Bioscience, Inc.
-0.61%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
Market Cap
$512.6M
Pitch Price
$6.56
Price Target
N/A
Dividend
N/A
EV/EBITDA
21.10
P/E
27.25
EV/Sales
3.62
Sector
Life Sciences Tools and Services
Category
growth
Pernas Research Passes On: Niagen Bioscience, Inc.
NAGE (pass): Longevity nutraceutical w/ patented NAD+ ingredient at $512M mcap, 23x EV/EBITDA. Supreme Court ruling allows NMN competitor back to market, removing regulatory advantage. Scientific consensus on efficacy still evolving. Valuation high amid renewed competition.
Read full article (1 min)